

8th Symposium on Glycosaminoglycans

Standardization and Harmonization of Methods for Analysis and Treatment of Acute Thromboembolism

October 26-28, 2000

Villa Vigoni, Lovenno (Como) / Italy



Organizers:

Job Harenberg,
1st Dept. of Medicine, Faculty of Clinical Medicine, Mannheim

Benito Casu,
Istituto Scientifico di Chimica e Biochimica "G. Ronzoni", Milan

Jürgen Jacob,
Baxter Deutschland GmbH, Hyland Immuno Division, Heidelberg

Welcome to Villa Vigoni!

It is the eighth time that the staff of Villa Vigoni hosts our symposium on glycosaminoglycan-protein binding, biological implications, unresolved issues in venous and arterial thromboembolism and standardization of methods for measurement of direct thrombin inhibitors - others than glycosaminoglycans. Since the knowledge in this field is expanding, the Italian and German colleagues of this research area decided to include a clinical session on the status and perspectives of the clinical application of antithrombin during the meeting.

At the end of each session we have organized round table discussions on the selected topics of the program. We would like to invite all participants to discuss and comment on these topics. Manuscripts of the presentations may be published in a regular volume of Seminars in Thrombosis and Hemostasis.

Please do not hesitate to contact the organizers of the symposium in the case of difficulties concerning transportation, accommodation or other problems with regard to the symposium.

We thank Professor Venturelli and his collaborators for enabling this symposium at Villa Vigoni.

Job Harenberg

Benito Casu

Jürgen Jacob

Thursday, October 26th, 2000

Arrival: until 12.00 a.m.
12.30 *Lunch in Villa Vigoni*

Session I: **Biotechnological heparin**

14. 00-14.10: **B. Casu, Milan and J. Harenberg, Mannheim:**

Welcome and introduction

Chairmen: **R. Paoletti, Milano and D.L. Heene, Mannheim**

14.10-14.30: **U. Lindahl, Uppsala:**

Biotechnological routes in generating heparin-like saccharides: a successful European project

14.30-14.50: **A. Naggi, Milan:**

Modulation of sulfation patterns of heparin and heparan sulfate backbones

14.50-15.10: **P. Oreste, Milan:**

Development of biotechnological heparins

15.10-15.30: **C. Sissi, Padova:** Modulation of antithrombin-mediated interaction with thrombin and factor Xa by semi-synthetic heparins with different sulfation patterns

15.30-15.50: **Discussion**

15.50-16.10: **Break**

16.10-16.30: **H. Baumann, Aachen:** The role of regioselectively sulfated and acylated polysaccharide coatings of biomaterials for reducing platelet and plasmaprotein adhesion

16.30-16.50: **S. Alban, Regensburg:** Structurally modified heparin-like polysaccharides

16.50-17.10: **U. Hoffmann, Mannheim:** Pharmacokinetics of LMWH

17.10-17.30: **Discussion**

19.30: Dinner

Friday, October 27th, 2000

Session II: **Structure-function relationship of heparins**

Chairmen: **U. Lindahl, Uppsala and U. Schmitz-Huebner, Herford**

9.00-9.20: **L. Liverani, Modena:** Open issues in the standardization of molecular size of LMW-heparins.

9.20-9.40: **M. Guerrini, Milano:** Active conformation of sulfated iduronic acid of heparin oligosaccharides in the presence of antithrombin and FGF-1

9.40-10.00: **L. Sturiale, Milano:** MALDI mass spectrometry as a tool for characterizing heparin oligosaccharides and their interaction with proteins

10.00-10.20: **L. Piazzolo, Mannheim:** Inhibition of thrombin generation and platelets by glycosaminoglycans and antiplatelet drugs

10.20-10.40: **Discussion**

10.40-11.00: **Break**

11.00-11.20: **G. Huhle, Mannheim:** Influence of monoclonal heparin binding protein on the biological function of heparins

11.20-11.40: **A. Stemberger, Munich:** Clinical results of stents coated with anticoagulant and antiplatelet agents

11.40-12.00: **D. Gulba, Berlin:** Comparison of glycosaminoglycans and direct thrombin inhibitors in unstable angina

12.00-12.20: **Discussion**

12.30-14.00: Lunch

Friday, October 27, 2000

Session III: Structure-function relationship of heparins and hirudins

Chairman: E. Wenzel, Homburg/Saar and E.F. Mammen, Detroit

14.00-14.20: F. Markwardt, Erfurt: Development of direct thrombin inhibitors in comparison to glycosaminoglycans

14.20-14.40: A. Calatzis, Munich: A new approach to the monitoring of LMWH, UFH and hirudin: the prothrombinase induced clotting test

14.40-15.00 G. Nowak, Jena: Clinical monitoring of direct thrombin inhibitors

15.00-15.20: D. Prisco, Florence: Hirudins for treatment of thromboembolism

15.20-15.40: Discussion

15.40-16.00: Break

16.00 -16.20: D. Gustafsson, Mölndal: The discovery and early development of the first oral direct thrombin Inhibitor H 3765/95 - Melagatran

16.20-16.40: M. V. Huisman, Leiden: Development of the oral thrombin inhibitor melagatran for treatment of thromboembolism

16.40-17.00: E. Gray, Hertfordshire: Results of the international interlaboratory control study to determine direct thrombin inhibitors

17.00-17.20: Discussion

19.30: Dinner

Saturday, October 28, 2000

Session IV: Structure-function relationship of glycosaminoglycans

Chairmen: E. Seifried, Frankfurt and M. Palumbo, Padova

9.00-9.20: V.V. Kakkar, London: Thrombin inhibition by low-molecular weight heparins

9.20-9.40: B. Kemkes-Matthes, Gießen: Differentiation of glycosaminoglycans with regard to development of thrombocytopenia

9.40-10.00: A. Eldor, Tel-Aviv: The use of LMW-heparins for the management of thrombophilia and antiphospholipid syndrome during pregnancy

10.00-10.20: G. Gambaro: Antiproteinuric effect of Sulodexide in Diabetic nephropathy: the D.I.N.A.S. trial.

10.20-10.30: Discussion:

10.30-10.50: Break

10.50-11.10: K. Schrör, Düsseldorf: Mitogenic action of factor Xa on vascular smooth muscle cells - inhibition by heparins?

11.10-11.30: A.K. Kakkar, London: Non-anticoagulant, antitumor effects of glycosaminoglycans - Results from molecular analysis

11.30-12.00: M.B. Donati, S.M. Imbaro: Development and characterization of experimental models for the study of anticoagulants

12.00-12.20: Discussion

12.20: End of the symposium

12.30: Lunch

General Information**Social Program****Thursday, October 26, 2000****19.30:** *Dinner in Villa Vigoni***Friday, October 27, 2000****8.00-8.45:** *Breakfast***13.00 -14.00:** *Lunch in Villa Vigoni***19.30:** *Dinner in Villa Vigoni***Saturday, October 28, 2000****8.00-9.00:** ***Breakfast*****13.00 -14.00** *Lunch in Villa Vigoni***Departure:** ***after lunch*****Location of the Symposium:**

"Villa Vigoni e.V."

Via Giulio Vigoni 1

Lovenno di Menaggio

I-22017 Menaggio (Como)

Tel.: +39-0344/361 11

Fax: +39-0344/36 12 10

E-mail: segretaria.vv@villavigoni.it

Internet: <http://www.villavigoni.it>**Registration:** Thursday, October 26, 2000**Publication Deadline: 15.01.2001**

12-14 manuscripts will be published in

Seminars in Thrombosis and Haemostasis 2001, volume 3

Scientific correspondence:

Job Harenberg

1st Department of Medicine

Faculty of Clinical Medicine

University of Heidelberg

Theodor-Kutzer-Ufer

D-68167 Mannheim

Germany

Tel: +49/621/383-33 78, -27 89

Fax: +49/621/383-38 08

Email: J-Harenberg@t-online.de**Sponsors as of October 16th, 2000:**

Deutsche Forschungsgemeinschaft, Bonn

American Diagnostica GmbH, Pfungstadt

Astra Zeneca, Mölndal

Aventis Pharma GmbH, Bad Soden

Baxter Deutschland GmbH, Heidelberg

Boehringer Ingelheim Pharma KG, Ingelheim

Dade Behring GmbH, Marburg

DuPont Pharma, Bad Homburg

Italfarmaco, Milano

Keryx Biopharm, Jerusalem

Laboratori Derivati Organici, Vicenza

Merck KgaA, Darmstadt

Nicox, Sophia Antipolis

Novartis Pharma GmbH, Nürnberg

Pentapharm Ltd., Basel

Pharmacia & Upjohn GmbH, Erlangen

Sigma-Tau, Roma

Thiemann Arzneimittel GmbH, Waltrop